Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03225547
What this trial is testing

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsBreast Cancer
University of Chicago 24
Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116
Testing effectiveness (Phase 2)Ended earlyNCT04142060
What this trial is testing

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT05467891
What this trial is testing

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Locoregional RecurrenceHormone Receptor-positive Breast CancerHER2-negative Breast Cancer
Oana Danciu 200
Large-scale testing (Phase 3)Ended earlyNCT02730091
What this trial is testing

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon 98
Early research (Phase 1)Ended earlyNCT03284723
What this trial is testing

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Who this might be right for
Breast Neoplasms
Pfizer 95
Testing effectiveness (Phase 2)Study completedNCT03018080
What this trial is testing

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

Who this might be right for
Breast - FemaleMale Breast Cancer
Wake Forest University Health Sciences 40
Not applicableActive Not RecruitingNCT02515110
What this trial is testing

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Who this might be right for
Breast CancerNode-positive Breast CancerBreast Adenocarcinoma+2 more
Virginia Commonwealth University 137
Testing effectiveness (Phase 2)Study completedNCT02970682
What this trial is testing

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Evgen Pharma 60
Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Testing effectiveness (Phase 2)WithdrawnNCT05664893
What this trial is testing

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

Who this might be right for
HER2 Negative Breast Cancer Not Immediately Operated
Centre Antoine Lacassagne
Not applicableStudy completedNCT01840306
What this trial is testing

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Who this might be right for
Breast CancerHER2 Positive Breast CancerHER2 Negative Breast Cancer
Cancer Trials Ireland 330
Testing effectiveness (Phase 2)Ended earlyNCT01918306
What this trial is testing

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor Negative Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastTriple Negative Breast Cancer+3 more
Vanderbilt-Ingram Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00623233
What this trial is testing

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Eli Lilly and Company 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284
What this trial is testing

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Who this might be right for
ER+HER2- Breast Cancer
West China Hospital 55
Large-scale testing (Phase 3)Not Yet RecruitingNCT07213206
What this trial is testing

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 1,500
Early research (Phase 1)Study completedNCT02058381
What this trial is testing

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Pre-menopausal Breast CancerPI3K Pathway Inhibition
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Testing effectiveness (Phase 2)Active Not RecruitingNCT06100874
What this trial is testing

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Who this might be right for
Her 2 Positive Breast CancerBreast Cancer FemaleBreast Cancer Metastatic
Adrienne G. Waks 28
Next Page